Security
Type

 

Security
Class Title⁽¹⁾⁽²⁾

 

Fee
Calculation
Rule

 

Amount
Registered

 

 

Proposed
Maximum

Offering
Price Per
Share⁽⁵⁾

 

 

Maximum
Aggregate
Offering Price

 

 

Fee Rate

 

 

Amount of
Registration
Fee

 

Equity

 

Ordinary shares, no par value, as represented by American Depositary Shares

 

457(c)

 

 

8,097,167

 

$

1.18

 

$

9,554,657

 

 

$

0.0001476

 

 

$

1,410

 

Total Offering Amount

 

 

8,097,167

 

 

 

 

 

 

$

9,554,657

 

 

 

 

 

 

$

1,410

 

Total Fees Previously Paid

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

—

 

Total Fee Offsets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Fee Due

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

1,410

 

(1)

Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the Registrant is also registering hereunder an indeterminate number of additional ordinary shares, no par value per share (“Ordinary Shares”) that shall be issuable pursuant to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.

(2)

Ordinary Shares may be represented by American Depositary Shares (“ADSs”), each of which represents twenty (20) ordinary shares of Chemomab Therapeutics Ltd. (the “Registrant”). ADSs issuable upon deposit of the Ordinary Shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-229522).

(3)

These shares consist of up to 161,943,340 Ordinary Shares (equivalent of 8,097,167 ADSs), consisting of (i) 4,148,867 ADSs and (ii) 3,948,300 ADSs issuable upon the exercise of pre-funded warrants. All 8,097,167 ADSs are to be offered for resale by the selling shareholders named in the prospectus contained in this Registration Statement on Form F-3.

(4)

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act of 1933, as amended, based on the average of the equivalent high and low sales prices of the ADSs on the Nasdaq Capital Market on August 19, 2024.

(5)

The Registrant will not receive any proceeds from the sale of its ADSs by the selling shareholders.